ADX-covid-header

Next Generation Dx Summit features COVID-19 updates across four conferences: Enabling Point-of-Care Diagnostics, Point-of-Care Technologies, Advanced Diagnostics for Infectious Disease, and Diagnostics Reimbursement. Can't decide on a single program? We encourage program-hopping at the Next Generation Dx Summit to help attendees maximize their on-site experience.

CONFERENCE PROGRAMS:

track1-POCT tech

Enabling Point-of-Care Diagnostics

August 25-26, 2020
View Program

Presentations:

Geospatial “Hot Spots” Need Rapid Point-of-Care Diagnostics to Stop Highly Infectious Threats and Antimicrobial Resistance
Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, School of Medicine, University of California, Davis

Rapid Development of Diagnostic Tests for New Threats: 2019 Novel Coronavirus Pneumonia (COVID-19) and Other Pathogens
Timothy Minogue, Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases

Point-of-Care Molecular Diagnostics for Disease Outbreak Settings: The Path to the Future
Rachel Spurbeck, PhD, Principal Research Scientist, Health Outcomes and Biotechnology Solutions, Battelle Memorial Institute

Point-of-Care Technologies

August 26-27, 2020
View Program

Presentations:

The Next Generation of Continuous Diagnostic Sensors: A Case Study on the Breakthroughs for Sweat Biosensing
Jason Heikenfeld, PhD, Vice President, Operations, Office of Innovation; Professor and Director, Novel Device Laboratory, University of Cincinnati

Global Considerations with Nucleic Acid at POC
Nardev Ramanathan, PhD, Global Lead Analyst, Digital Transformation, Lux Research, Inc.

CASE STUDY: From AIDS to Ebola, Commercializing Rapid Tests for Infectious Disease
Stephen Tang, PhD, President & CEO, OraSure Technologies, Inc.


track4-POCT-infectious

Advanced Diagnostics for Infectious Disease

August 26-27, 2020
View Program

Presentations by:

DOD’s Pursuit of Pre-Symptomatic Non-Invasive Diagnostics
Edward Argenta, Science & Technology Manager, Biological & Chemical Technologies, Defense Threat Reduction Agency

The Biofire Pneumonia Panel: Does It Relate to Microbiological and Clinical Variables?
Kenneth Rand, MD, Medical Director, Clinical Microbiology Laboratory; Professor, Pathology and Medicine, University of Florida

Clinical Metagenomic Sequencing and Human Host Response: Changing the Diagnostic Paradigm?
Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine


track3-business

Coverage and Reimbursement for Advanced Diagnostics

August 25-26, 2020
View Program

Presentations:

Coding for The Frontlines: Establishing CPT® Codes for Novel Coronavirus (SARS-CoV-2) Tests
Zach Hochstetler, Director, CPT Editorial and Regulatory Services, American Medical Association, AMA

PANEL DISCUSSION: Hot Button Issues in Dx Reimbursement

Moderators:
Danielle Scelfo, Senior Director, Health Policy and Reimbursement, Hologic, Inc.
Ester Stein, MBA, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories

Panelists:
Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
Marc Hartstein, Principal, Health Policy Alternatives
Julie Khani, President, American Clinical Laboratory Association

REGISTER



Register by July 24 & SAVE $200! 

Premier Sponsors


Corporate Sponsors


View All Sponsors